StreetInsider.com News Articles

BTIG Upgrades Outlook Therapeutics Inc. (OTLK) to Buy

Mon, 27 Jul 2026 06:09:20 -0400

BTIG analyst Julian Harrison upgraded Outlook Therapeutics Inc. (NASDAQ: OTLK) from Neutral to Buy with a price target of $4.00.

The analyst comments "We are upgrading OTLK to BUY and a $4 PT, following LYTENAVA's approval in wet AMD on Friday afternoon by the FDA. The approval supported by a formal dispute resolution is largely unprecedented, and represents a pivot from OTLK being a regulatory debate to a commercial story. LYTENAVA is now confirmed as the only FDA-approved ophthalmic bevacizumab (anti-VEGF mAb) formulation for wet AMD (wAMD). Physicians currently utilize compounded bevacizumab for anti-VEGF wAMD treatment, though limited oversight typically transfers

BTIG Upgrades Outlook Therapeutics Inc. (OTLK) to Buy

Mon, 27 Jul 2026 06:09:20 -0400

BTIG analyst Julian Harrison upgraded Outlook Therapeutics Inc. (NASDAQ: OTLK) from Neutral to Buy with a price target of $4.00.

Form 8-K Outlook Therapeutics, For: Jul 24

Fri, 24 Jul 2026 17:01:00 -0400

si-local-file:///var/storage/secattach/20260724/26814227.html

Form 8-K Outlook Therapeutics, For: Jul 24

Fri, 24 Jul 2026 17:01:00 -0400

si-local-file:///var/storage/secattach/20260724/26814227.html

FDA approves Outlook Therapeutics' Lytenava for wet AMD

Fri, 24 Jul 2026 14:40:13 -0400

Outlook Therapeutics, Inc. (Nasdaq: OTLK) announced that the U.S. Food and Drug Administration has approved LYTENAVA (bevacizumab-vikg) for the treatment of neovascular age-related macular degeneration, commonly known as wet AMD.

According to a company statement, LYTENAVA is the first FDA-approved ophthalmic formulation of bevacizumab in the United States. The drug was developed specifically for intravitreal administration, as opposed to prior bevacizumab use in ophthalmology, which relied on repackaged formulations originally intended for intravenous use.

Outlook Therapeutics said it anticipates LYTENAVA will receive 12 years of Reference Product Exclusivity under the Biologics Price Competition and Innovation Act. The company expects to make the

Outlook Therapeutics Announces LYTENAVA™ FDA Approval as the First and Only FDA-Approved Ophthalmic Bevacizumab for the Treatment of Wet AMD

Fri, 24 Jul 2026 14:40:00 -0400

Landmark FDA Approval Is an Important Milestone in Retina Care, Bringing Patients and Physicians an Ophthalmic Bevacizumab Developed Specifically for the Eye Following Years of Rigorous Clinical and Regulatory Evaluation

Company Launches Commercial Franchise Positioned to Establish a New Standard as an FDA-Approved Bevacizumab Therapy Across the Approximately $8.5 Billion U.S. Retina Market

Anticipated 12 Years of Market Exclusivity Under the Biologics Price Competition and Innovation Act (BPCIA)

ISELIN, N.J., July 24, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the development

Outlook Therapeutics Announces LYTENAVA™ FDA Approval as the First and Only FDA-Approved Ophthalmic Bevacizumab for the Treatment of Wet AMD

Fri, 24 Jul 2026 14:40:00 -0400

Company Launches Commercial Franchise Positioned to Establish a New Standard as an FDA-Approved Bevacizumab Therapy Across the Approximately $8.5 Billion U.S. Retina Market

Anticipated 12 Years of Market Exclusivity Under the Biologics Price Competition and Innovation Act (BPCIA)

ISELIN, N.J., July 24, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the development

Outlook Therapeutics (OTLK) halted, news pending

Fri, 24 Jul 2026 13:40:10 -0400

Outlook Therapeutics (OTLK) halted, news pending

Fri, 24 Jul 2026 13:40:10 -0400

Outlook Therapeutics (OTLK) halted, news pending

Form 8-K Outlook Therapeutics, For: Jul 21

Fri, 24 Jul 2026 06:02:00 -0400

si-local-file:///var/storage/secattach/20260724/26809998.html

Form 8-K Outlook Therapeutics, For: Jul 21

Fri, 24 Jul 2026 06:02:00 -0400

si-local-file:///var/storage/secattach/20260724/26809998.html

Form 4 Outlook Therapeutics, For: Jul 21 Filed by: KENYON LAWRENCE A

Thu, 23 Jul 2026 19:50:00 -0400

si-local-file:///var/storage/secattach/20260723/26809375.html

Form 4 Outlook Therapeutics, For: Jul 21 Filed by: KENYON LAWRENCE A

Thu, 23 Jul 2026 19:50:00 -0400

si-local-file:///var/storage/secattach/20260723/26809375.html

Form 4 Outlook Therapeutics, For: Jul 21 Filed by: Jahr Robert Charles

Thu, 23 Jul 2026 19:34:00 -0400

si-local-file:///var/storage/secattach/20260723/26809357.html

Form 4 Outlook Therapeutics, For: Jul 21 Filed by: Jahr Robert Charles

Thu, 23 Jul 2026 19:34:00 -0400

si-local-file:///var/storage/secattach/20260723/26809357.html

Form EFFECT Outlook Therapeutics,

Wed, 22 Jul 2026 06:04:00 -0400

si-local-file:///var/storage/secattach/20260722/26797641.html

Form EFFECT Outlook Therapeutics,

Wed, 22 Jul 2026 06:04:00 -0400

si-local-file:///var/storage/secattach/20260722/26797641.html

Form 424B3 Outlook Therapeutics,

Tue, 21 Jul 2026 16:37:00 -0400

si-local-file:///var/storage/secattach/20260721/26796158.html

Form 424B3 Outlook Therapeutics,

Tue, 21 Jul 2026 16:37:00 -0400

si-local-file:///var/storage/secattach/20260721/26796158.html

Outlook Therapeutics (OTLK) files for 17.3M share offering by selling stockholders

Fri, 17 Jul 2026 16:09:13 -0400

Outlook Therapeutics (NASDAQ: OTLK) has filed for up to 17,258,065 share offering by selling stockholders.

Outlook Therapeutics (OTLK) files for 17.3M share offering by selling stockholders

Fri, 17 Jul 2026 16:09:13 -0400

Outlook Therapeutics (NASDAQ: OTLK) has filed for up to 17,258,065 share offering by selling stockholders.

Form S-3 Outlook Therapeutics,

Fri, 17 Jul 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260717/26784368.html

Form S-3 Outlook Therapeutics,

Fri, 17 Jul 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260717/26784368.html

Form 8-K Outlook Therapeutics, For: Jul 16

Thu, 16 Jul 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260716/26779680.html

Form 8-K Outlook Therapeutics, For: Jul 16

Thu, 16 Jul 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260716/26779680.html